NCT06309966进行中（未招募）2 期
A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 390
- 试验地点
- 289
- 主要终点
- Change from Baseline in 28-day average seizure frequency
研究概览
简要总结
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female participants 18 to 75 years of age at time of consent.
- •Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.
- •a. Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures with clinically observable signs and/or symptoms iii. Focal to bilateral tonic-clonic seizures
- •Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.
- •Ability to keep accurate seizure diaries
- •Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total
排除标准
- •History of status epilepticus (convulsive status epilepticus for > 5 minutes or focal status epilepticus with impaired consciousness for > 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure.
- •History of repetitive/cluster seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit and during observation phase.
- •Resection neurosurgery for seizures <4 months prior to the screening visit.
- •Radiosurgery performed <2 years prior to the screening visit.
- •Subjects with only focal aware nonmotor seizures which involve subjective sensory or psychic phenomena only, without impairment of consciousness or awareness (formally called simple partial seizures), with or without ictal EEG correlation with clinical symptoms.
- •Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator
研究组 & 干预措施
BHV-7000 75 mg
Experimental
干预措施: BHV-7000 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
BHV-7000 50 mg
Experimental
干预措施: BHV-7000 (Drug)
结局指标
主要结局
Change from Baseline in 28-day average seizure frequency
时间窗: Baseline, Week 8 to Week 16
To compare the efficacy of 75mg of BHV-7000 to placebo as an adjunctive therapy for refractory focal onset epilepsy as measured by the change from OP (observational phase) in 28-day average seizure frequency. The primary objective will be measured by comparing the observation phase (8 weeks) to the 8-week double-blind treatment phase.
次要结局
- Change from Baseline in 28-day average seizure frequency(Baseline, Week 8 to Week 16)
- Percentage of Participants with at at least 50% reduction in seizure frequency per month(Baseline, Week 8 to Week 16)
- Change from Baseline in 28-day average seizure frequency during first month of treatment(Baseline, Week 8 to Week 12)
- Percentage of Participants with at at least 75% reduction in seizure frequency per month(Baseline, Week 8 to Week 16)
- Percentage of Participants with seizure freedom during DB Phase(Week 8 to Week 16)
- Change from baseline in 7-day adjusted seizure frequency during first week of treatment(Baseline, Week 8 to Week 9)
- Change from baseline in Patient Global Impression of Change (PGI-C)(Baseline, Week 16)
- Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs(Week 8 to Week 16)
- Number of Participants With Clinically Significant Laboratory Abnormalities(Week 8 to Week 16)
研究者
研究点 (289)
Loading locations...
相似试验
招募中
2 期
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyNCT06132893Biohaven Therapeutics Ltd.390
已完成
2 期
BHV-7000 Acute Treatment of Bipolar ManiaBipolar DisorderNCT06419582Biohaven Therapeutics Ltd.274
已完成
2 期
Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionMajor Depressive DisorderNCT06419608Biohaven Therapeutics Ltd.336
终止
2 期
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic SeizuresGeneralized EpilepsyNCT06425159Biohaven Therapeutics Ltd.27
已完成
3 期
Safety and Efficacy in Adult Subjects With Acute MigrainesMigraine, With or Without AuraNCT03237845Pfizer1,499